| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/10428194.2017.1349899 |
| P698 | PubMed publication ID | 28750570 |
| P2093 | author name string | Sriram Balasubramanian | |
| Yang Liu | |||
| Michael Schaffer | |||
| Jennifer Yang | |||
| Shalini Chaturvedi | |||
| Matthias Versele | |||
| Rongzhen Lu | |||
| Cuc Davis | |||
| Regina Aquino | |||
| Emily Stepanchick | |||
| P2860 | cites work | Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. | Q55070853 |
| Small-molecule inhibition of BRDT for male contraception | Q24616901 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 | ||
| Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways | Q24652565 | ||
| A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma | Q24680233 | ||
| Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling | Q27860529 | ||
| Cancer statistics, 2013 | Q27860762 | ||
| Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma | Q28649793 | ||
| The NCI60 human tumour cell line anticancer drug screen | Q29614975 | ||
| Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 | ||
| Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma | Q30371806 | ||
| High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells | Q30433183 | ||
| Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study | Q33416593 | ||
| Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study | Q33428297 | ||
| Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies | Q33893704 | ||
| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia | Q34052075 | ||
| Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia | Q34392488 | ||
| Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. | Q34472091 | ||
| IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells | Q34636880 | ||
| Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma | Q36335846 | ||
| Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells | Q36369816 | ||
| Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma. | Q37469613 | ||
| Ibrutinib for B cell malignancies | Q37555418 | ||
| Targeting pathological B cell receptor signalling in lymphoid malignancies | Q38085501 | ||
| Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study | Q38670952 | ||
| Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4. | Q38859723 | ||
| Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. | Q40716705 | ||
| A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. | Q42285217 | ||
| Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. | Q43031217 | ||
| Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation | Q44926251 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P921 | main subject | ibrutinib | Q5984881 |
| P304 | page(s) | 931-940 | |
| P577 | publication date | 2017-07-28 | |
| P1433 | published in | Leukemia & Lymphoma | Q6534493 |
| P1476 | title | Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen. | |
| P478 | volume | 59 |
| Q91623240 | Bromodomains: a new target class for drug development |
| Q90245956 | Co-inhibition of BET proteins and PI3Kα triggers mitochondrial apoptosis in rhabdomyosarcoma cells |
| Q90066183 | Differential expression of N-linked oligosaccharides in methotrexate-resistant primary central nervous system lymphoma cells |
| Q48169839 | Direct and indirect approaches to identify drug modes of action. |
| Q92150213 | Emerging epigenetic-modulating therapies in lymphoma |
| Q89767697 | Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy |
| Q58790081 | Recent advances in combinatorial drug screening and synergy scoring |
| Q94671635 | Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies |
Search more.